Navigation Links
Decade-long trial confirms benefts of steroid withdrawal for transplant patients
Date:8/23/2010

CINCINNATIA University of Cincinnati (UC) analysis of 10 years of data from local kidney transplant patients shows that patients removed from a corticosteroid regimen shortly after surgery have better graft survival rates, better survival rates and fewer cardiovascular events than patients kept on the traditional regimen of long-term steroids.

The analysis shows that, out of 904 patients transplanted at UC Health University Hospital and Christ Hospital, early corticosteroids withdrawal (ECSWD) patients had an 83.8 percent graft survival rate and a 91.7 percent patient survival rate, as compared to 68.6 percent graft survival and 83.6 percent patient survival for chronic corticosteroid (CCS) patients. UC's survival rates were numerically higher than national rates from the United Network for Organ Sharing (UNOS) registry.

Corticosteroids, in combination with other immunosuppressive drugs, have historically been prescribed to transplant patients to help suppress the body's immune response and allow the transplanted organ to function after surgery. But they also come with an increased risk of high blood pressure, high cholesterol, weight gain, diabetes and cardiovascular disease and events.

With development of better immunosuppressive drugs, that cardiovascular risk has come to be the chief concern for transplant patients' survival, not the loss of their new organ, explains Adele Rike Shields, PharmD, UC research assistant professor of surgery and clinical transplant pharmacist at Christ Hospital.

Four years ago, Shields says, UC researchers showed ECSWD patients had a significant reduction in cardiovascular events as opposed to CCS patients. But researchers still weren't certain whether ECSWD patients have worse long-term graft functioning due to a risk of acute rejection of the organ.

With 10 years of data, Shields says they can now answer that question definitively.

"This is the first study with enough long-term follow-up to show that we're not causing an increase in graft loss with early corticosteroid withdrawal," says Shields. "We have just as good, if not better graft results and the patients' survival is better because of their reduced cardiovascular risk."

She presented the work last week at the International Congress of The Transplantation Society in Vancouver.

Not only does the analysis show that ECSWD patients have decreased cardiovascular events, Shields says they also have a reduced risk of malignancies not associated with immunosuppressive drugs. ECSWD patients showed a 2.2 percent rate of non-PTLD cancer, one-third the rate of malignancies in CCS patients. PTLD, or post-transplant lymphoproliferative disorder, is the name given to a group of lymphomas occurring in immunosuppressed patients.

UC transplant researchers have focused on steroid withdrawal under E. Steve Woodle, MD, chief of the division of transplant surgery. Woodle calls the data from the 10-year analysis "highly statistically significant."

"To my knowledge, we are the first of any transplant program to demonstrate this magnitude of an effect," he says. "We now know without a doubt that our original hypothesis generated more than 15 years ago does indeed benefit our patients. This is the final nail in the coffin for steroid based immunosuppression for our program."


'/>"/>

Contact: Katy Cosse
kathryn.cosse@uc.edu
513-558-0207
University of Cincinnati Academic Health Center
Source:Eurekalert

Related medicine news :

1. Trial Therapy Improves Melanoma Survival
2. CRF announces featured clinical trials to be presented at TCT 2010
3. Clinical trials: Comprehension unaffected by simplified consent forms or payment
4. Clinical trials abroad: Making non-English language consent forms readable
5. Human clinical trial of NIH-developed dengue vaccine begins
6. CRF announces late breaking trials and first report investigations to be presented at TCT 2010
7. Drug trials funded by industry are more likely to publish favorable results
8. Clinical trials can be improved by managing the learning curve
9. Sickle cell treatment developed at LA BioMed enters Phase 3 clinical trial
10. Microbicide trial results a turning point for HIV prevention, says team testing same gel
11. Many False-Positive HIV Test Results for Those in AIDS Vaccine Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced ... feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as a ... has released tools for healthy coping following a traumatic event. , Trauma sufferers tend ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... Comfort ... the American Cancer Society and the Road To Recovery® program to drive cancer patients ... seniors and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
Breaking Medicine Technology: